MONTREAL, Jan. 29, 2018 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA) (TSX: BIOA) - a leader in renewable materials, is pleasedto announce the results of an independent commercial trial conducted with a leading North American feed formulator, on the effectiveness of BioAmber's Bio-Succinic Acid, BIO-SA™, as an ingredient in Animal Feed for nursery pigs.
In a commercial
Succinic acid is listed by The Association of American Feed Control Officials (AAFCO) and the European Union Register of Feed Additives, for immediate use in animal feed formulations.
BioAmber CEO Richard Eno stated, "Animal feed represents an extremely large market opportunity for BioAmber, and these studies show that our product could play an important role in antibiotic replacement. BIO-SA™ can assist the Animal Feed industry's continued move away from antibiotics as well as its ongoing drive for enhanced feed productivity, while at the same time improving the overall sustainability of the supply chain. Formulation and early stage market testing continues as we move towards ongoing, commercial sales in this important sector."
BioAmber will be attending the International Production & Processing Expo (IPPE), the world's largest annual poultry, feed and meat technology exposition, in Atlanta, GA from January 30 through February 1, 2018. Please contact Paul Petersen – Vice President of Sales at firstname.lastname@example.org for more information.
About BioAmberBioAmber (NYSE: BIOA, TSX: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com
Forward-Looking Statements This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward- looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber's public filings with the SEC, including the "Risk Factors" section of BioAmber's Annual Report on Form 10-K and the most recent quarterly report on Form 10-Q.
SOURCE BioAmber Inc.
Subscribe to our Free Newsletters!
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...View All